This may be attributable to its indication for HER2-positive advanced breast cancer in patients with multiple prior lines of therapy [44], placing its use in a different treatment phase from other anti-HER2 monoclonal antibodies. This evidence concerns the gene ERBB2 and breast carcinoma.